Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: RXBIO, INC.
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2018-09-01 to 2022-06-30
Current total value of award: $4591511.92
Description: IND-ENABLING DEVELOPMENT OF RX100 AS A MEDICAL COUNTERMEASURE FOR GASTROINTESTINAL ACUTE RADIATION SYNDROME.